Songyun Wang

Dr. Songyun Wang

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in Journal of Controlled Release
Verified
Journal Article
Closed access
HHHaoyuan Hu
Haoyuan Hu
JZJiahui Zhao
Jiahui Zhao
KMKezhong Ma
Kezhong Ma
JWJiale Wang
Jiale Wang
XWXinqi Wang
Xinqi Wang
SWSongyun Wang
Songyun Wang

2 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
TZTao Zhang
Tao Zhang
HHHaoyuan Hu
Haoyuan Hu
HJHong Jiang
Hong Jiang
ZWZhen Wang
Zhen Wang
JLJinfeng Lin
Jinfeng Lin
Benpeng ZhuBenpeng Zhu
Benpeng Zhu
High-performance lead-free K0.5Na0.5NbO3 piezoelectric ceramics present a practical alternative to lead-containing counterparts by effectively reducing potential environmental hazards. This advancement is particularly relevant to the development of ferroelectric heterojunction devices for biomedical applications. Here, we design and fabricate a frequency-adjustable ferroelectric heterojunction based on the developed K0.5Na0.5NbO3 piezoelectric ceramics with a high piezoelectric coefficient (d 33 = 680 pC/N). By leveraging flexible encapsulation, the heterojunction achieves miniaturization (φ = 13.3 mm, h = 2.28 mm) and suitability for implantation. After penetrating the rat skull, the ultrasound generated by the heterojunction at a frequency of 3 MHz reaches a focal depth of about 7.9 mm, a focal width of approximately 480 μm at −6 dB, and millimeter-scale continuous focal tuning (1.5 mm) within a narrow frequency range (2.7–3.3 MHz). Additionally, the implanted heterojunction enables long-term and high-precision transcranial neuromodulation, and consequently yields therapeutic effects in a myocardial infarction animal model. Collectively, this study highlights a viable strategy for developing and applying lead-free ferroelectric heterojunctions, expanding their potential in brain modulation, and providing new insights into clinical treatments of myocardial infarction.

10 July 2024 in Ultrasonics
Verified
Journal Article
Closed access
HHHaoyuan Hu
Haoyuan Hu
CHChanghao Hu
Changhao Hu
WGWei Guo
Wei Guo
Benpeng ZhuBenpeng Zhu
Benpeng Zhu
SWSongyun Wang
Songyun Wang

30 November 2023 in Heart Rhythm
Verified
Journal Article
Closed access
CXChunrong Xiang
Chunrong Xiang
YCYe Cheng
Ye Cheng
XYXiaomei Yu
Xiaomei Yu
TMTianlong Mao
Tianlong Mao
HLHao Luo
Hao Luo
HJHong Jiang
Hong Jiang

1 October 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
ASAtsushi Suzuki
Atsushi Suzuki
ADAmanda J. Deisher
Amanda J. Deisher
MRMaryam E. Rettmann
Maryam E. Rettmann
HLH. Immo Lehmann
H. Immo Lehmann
SHStephan Hohmann
Stephan Hohmann
DPDouglas L. Packer
Douglas L. Packer
Background - Proton beam therapy offers radiophysical properties that are appealing for noninvasive arrhythmia elimination. This study was conducted to use scanned proton beams for ablation of cardiac tissue, investigate electrophysiologic outcomes, and characterize the process of lesion formation in a porcine model using particle therapy. Methods - Twenty-five animals received scanned proton beam irradiation. ECG-gated CT scans were acquired at end-expiration breath hold. Structures (atrioventricular junction [AVJ] or left ventricular myocardium [LV]) and organs at risk were contoured. Doses of 30, 40, and 55Gy were delivered during expiration to the AVJ (AVJ; n=5) and LV myocardium (LV; n=20) of intact animals. Results - In this study, procedural success was tracked by pacemaker interrogation in the AVJ group, time-course magnetic resonance imaging (MR) in the LV group, and correlation of lesion outcomes displayed in gross and microscopic pathology. Protein extraction (active caspase-3) was performed to investigate tissue apoptosis. Doses of 40 and 55Gy caused slowing and interruption of cardiac impulse propagation at the AVJ. In 40 LV irradiated targets, all lesions were identified on MR after twelve weeks, being consistent with outcomes from gross pathology. In the majority of cases, lesion size plateaued between 12 and 16 weeks. Active caspase-3 was seen in lesions 12 and 16 weeks after irradiation, but not after 20 weeks. Conclusions - Scanned proton beams can be used as a tool for catheter-free ablation, and time-course of tissue apoptosis was consistent with lesion maturation.

8 July 2019 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
SWSongyun Wang
Songyun Wang
LWLin Wu
Lin Wu
XLXuemeng Li
Xuemeng Li
BLBinxun Li
Binxun Li
YZYi Zhai
Yi Zhai
HJHong Jiang
Hong Jiang
Sympathetic overactivation and inflammation are two major mediators to post-myocardial ischemia-reperfusion (I/R)-induced ventricular arrhythmia (VA). The vicious cycle between microglia and sympathetic activation plays an important role in sympathetic hyperactivity related to cardiovascular diseases. Recently, studies have shown that microglial activation might be attenuated by light-emitting diode (LED) therapy. Therefore, we hypothesized that LED therapy might protect against myocardial I/R-induced VAs by attenuating microglial and sympathetic activation. Thirty-six male anesthetized rats were randomized into four groups: control group (n = 6), LED group (n = 6), I/R group (n = 12), and LED+I/R group (n = 12). I/R was generated by left anterior descending artery occlusion for 30 min followed by 3 h reperfusion. ECG and left stellate ganglion (LSG) neural activity were recorded continuously. After 3 h reperfusion, a programmed stimulation protocol was conducted to test the inducibility of VA. Furthermore, we extracted the brain tissue to examine the microglial activation, and the peri-ischemic myocardium to examine the expression of NGF and inflammatory cytokines (IL-1β, IL-18, IL-6, and TNF-α). As compared to the I/R group, LED illumination significantly inhibited the LSG neural activity (P < 0.01) and reduced the inducibility of VAs (arrhythmia score 4.417 ± 0.358 vs. 3 ± 0.3257, P < 0.01) in the LED+I/R group. Furthermore, LED significantly attenuated microglial activation and downregulated the expression of inflammatory cytokines and NGF in the peri-infarct myocardium. LED therapy may protect against myocardial I/R-induced VAs by central and peripheral neuro-immune regulation.